I agree with getting 75 patients worth of data before taking it to the FDA. We have been guilty of prematurely approaching the FDA (BTD for mTNBC), and doing so with an insufficient number could really be damaging. If we can read the data at 75 and it looks good, that's the move. If the FDA requires us to fully enroll the 390, we are seriously screwed with regards to COVID and the price will be back at $1.20.